Advertisement

Topics

PubMed Journals Articles About "Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated" RSS

19:55 EDT 21st August 2018 | BioPortfolio

Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated articles that have been published worldwide.

More Information about "Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated" on BioPortfolio

We have published hundreds of Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated news stories on BioPortfolio along with dozens of Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated Clinical Trials and PubMed Articles about Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated Companies in our database. You can also find out about relevant Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated Drugs and Medications on this site too.

Showing "Acticor Biotech Pharmaceuticals Healthcare Deals Alliances Profile Updated" PubMed Articles 1–25 of 7,100+

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Millennium Pharmaceuticals, and Onyx Pharmaceuticals; and is a member of advisory boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte, Kite, Legend Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals.


Hospital purchasing alliances: Ten years after.

Most hospitals outsource supply procurement to purchasing alliances, or group purchasing organizations (GPOs). Despite their early 20th century origin, we lack both national and trend data on alliance utilization, services, and performance. The topic is important as alliances help hospitals control costs, enjoy tailwinds from affiliated regional/local alliances, and face headwinds from hospital self-contracting and criticism of certain business practices.

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency close to 100%. Their incomplete removal results in a continuous discharge of pharmaceuticals into the environment. To assess the profile of contamination of influents and effluents over a day, a set of 83 pharmaceuticals were evaluated hourly in a WWTP in Leiria, Portugal. The composite samples of the influent and ...


Biotech Crop Planting Resumes High Adoption in 2016.

The global area of biotech crops in 2016 increased from 179.7 million hectares to 185.1 million hectares, a 3% increase equivalent to 5.4 million hectares. Some 26 countries planted biotech crops, 19 of which were developing countries and seven were industrial. Information and data collected from various credible sources showed variations from the previous year. Fluctuations in biotech crop area (both increases and decreases) are influenced by factors including, among others, acceptance and commercializatio...

Evaluation of the LIA-ANA-Profile-17S for the detection of autoantibodies to nuclear antigens.

The diagnostic tests for autoimmune disease include screening for autoantibodies for nuclear antigens (ANA) and antibodies against extractable nuclear antigens (ENA). Using the line immunoassay (LIA) method, various kinds of ENA antibodies can be detected simultaneously. We evaluated the performance of the newly launched LIA-ANA-Profile-17S (Shenzhen YHLO Biotech, Shenzhen, China) as compared to a conventional LIA kit.

The prevalence of persistence and related health status: An analysis of persistently high healthcare costs in the short term and medium term.

Understanding whether high healthcare costs for individuals persist over time is critical for the development of policies that aim to reduce the prevalence of high cost patients. And while high healthcare costs will occur in any given year based on the prevalence of certain morbidities and acute conditions, a large random component of the distribution means that it is rarely the same people driving the bulk of healthcare expenditures. Using administrative data for over 250,000 Australian residents for the y...

Comments on: "Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials".

Cardiovascular Risk Profile of Transgender Women with HIV: A U.S. Healthcare Database Study.

We sought to characterize the cardiovascular disease (CVD) risk factor profile of transgender women with HIV identified through a U.S. healthcare database. Compared with age- and race-matched cisgender men with HIV, transgender women with HIV had an increased prevalence of anemia and lower absolute hemoglobin levels. HIV control was sub-optimal and prevalence of HCV co-infection was high among transgender women. Further study of non-traditional CVD risk factors/immune activation among transgender women with...

Nationwide Healthcare utilization among children with epilepsy in the United States: 2003-2014.

Epilepsy is particularly frequent among children, yet updated and nationwide healthcare utilization estimates are scanty in the United States.

Reply to the Comments on "Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials.

The Second Society for Simulation in Healthcare Research Summit: Beyond our Boundaries.

In this article, we report on the Second Society for Simulation in Healthcare Research Summit held in 2017. This meeting succeeded the First Research Summit from 2011 with the goal of advancing the scope of healthcare simulation research. During the one and a half day summit, some of the world's leading experts in simulation, healthcare, and simulation in healthcare convened to discuss ideas about what research goals would be most beneficial to the healthcare simulation community, and what could be done to ...

Strong alliances to improve stroke care.

A Future-Focused Approach to Behavioral Healthcare.

Funding profiles of multisector health care alliances and their positioning for sustainability.

Purpose The purpose of this paper is to examine the relationship between different aspects of alliance funding profiles (e.g. range of sources, dependence on specific sources) and participant' perceptions of how well the organization is positioned for the future. Design/methodology/approach A mixed method study in the context of eight alliances participating in the Robert Wood Johnson Foundation's Aligning Forces for Quality program. Data collection approaches included surveys of alliance participants and s...

Healthcare use for children with complex needs: using routine health data linked to a multiethnic, ongoing birth cohort.

Congenital anomaly (CA) are a leading cause of disease, death and disability for children throughout the world. Many have complex and varying healthcare needs which are not well understood. Our aim was to analyse the healthcare needs of children with CA and examine how that healthcare is delivered.

Second-quarter biotech job picture.

The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Short Version).

The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS) deals with the use of microbubble ultrasound contrast outside the liver in the many established and emerging applications.

The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version).

The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS) deals with the use of microbubble ultrasound contrast outside the liver in the many established and emerging applications.

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause of familial hypercholesterolemia. However, multiple mutations in various other genes are also associated with high LDL cholesterol and even familial hypercholesterolemia. Thus, pharmaceuticals that target these genes and proteins might be attractive treatment options to reduce LDL cholesterol. This review provi...

Research biotech patenting 2017.

Public biotech in 2017-the numbers.

Gates unveils biotech-within-a-charity.

New Nonprofit Biotech From Bill and Melinda Gates.

Toward Live Virtual Constructive Simulations in Healthcare Learning.

This article explores the combination of live, virtual, and constructive (LVC) simulations in healthcare. Live, virtual, and constructive simulations have long existed in the military, but their consideration (and deployment) in medical and healthcare domains is relatively new. We conducted a review on LVC- its current application in the military domain -and highlight an approach, challenges, and present suggestions for its implementation in healthcare learning. Furthermore, based on the state of the art in...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product related caused by protein degradation occurring throughout the life history of a product. Although the pharmaceutical biotechnology industry has made great progress in improving bulk and drug product manufacturing as well as company-controlled storage and transportation conditions to minimize the level of degra...


Advertisement
Quick Search
Advertisement
Advertisement